Insights
Insights
Notes on NMPA registration, clinical evaluation, manuscript review and medical translation, drawn from our project work.
NMPA registration and clinical evaluation
China market entry for medical devices: an NMPA registration guide
The six steps of NMPA registration, how NMPA compares with FDA and TGA, and the questions overseas manufacturers ask most often.
Why an NMPA clinical evaluation does not require a state-of-the-art analysis
MDR benchmarks a device against the whole field. NMPA compares it with one device already marketed in China.
Can FDA clinical data be used in an NMPA submission?
Why a 510(k) predicate may not qualify as an NMPA comparator, and how FDA clinical data can still support the evaluation.
Answering an NMPA request for a representativeness argument
An indication expansion debrief: completeness, representativeness and engineering safety factors in one chain of reasoning.
Reviewing a client-drafted CER: four recurring problems
Equivalence evidence, device boundaries, indicator consistency and citations: what two review rounds found.
Manuscript review
Four manuscripts, the same three logic failures
Overclaimed conclusions, unresolved contradictions and statistics that support no claim. None is visible at sentence level.
What does manuscript editing actually fix?
Fluent manuscripts can still fail peer review. Editing checks whether claims, aims and terms match the evidence.
Translation and language
Does English written in different countries read differently?
How first-language habits shape word choice and sentence patterns in written English.
AI interpretation is here. Does it solve cross-border communication?
The hardest barrier in China–West projects is two ways of working, not two languages.
Have a question about your project?
Tell us about your device, manuscript or documents and your timeline. We will reply with a proposed scope.